ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes

News
Article

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

A child has their blood sugar tested using a digital glucometer. Image credit: ©Africa Studio – stock.adobe.com

The study underscored the significant associations seen with older age, longer disease duration, earlier disease onset and some modifiable risk factors. Image credit: ©Africa Studio – stock.adobe.com

A chart review showed that diabetic retinopathy (DR) is associated with older age, longer duration of type 1 diabetes, earlier onset of type 1 diabetes and some modifiable risk factors.

The results, according to first author Konstantina Sampani, MD, indicated that maintaining control of blood pressure (BP) and hemoglobin A1c (HbA1c) are key to preventing the onset of DR. Dr Sampani, who is from the Joslin Diabetes Center Beetham Eye Institute, Boston, Massachusetts, presented the findings of her group at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle.

The investigators conducted a retrospective chart review of patients’ demographic and clinical data from 2005 to 2020.

The investigators used spectral-domain optical coherence tomography (SD-OCT) macular scans for a subset of patients and automated retinal layer segmentation to determine the inner and outer layers (IRL, ORL). The researchers sought correlations between the patient demographics, body mass index (BMI), BP, HbA1c, and retinal layer cell thickness and volume with the presence of DR, she recounted.

Key findings

The demographic data from the cohort were as follows. A total of 1,359 patients (2,704 eyes; 49.6% female; mean age, 13.7±4.3 years) were included. The mean duration of the type 1 diabetes was 7.0±5.2 years; the mean age at onset of type 1 diabetes, 7.7±4.7 years; mean HbA1c, 8.4±1.3%; mean BMI, 21.9±4.3; mean systolic BP, 109.2±10.4; and mean diastolic BP, 65.8±7.4.

Of the 2,704 eyes, 139 (5.14%) had DR, of which 5.1% was nonproliferative and 0.04% was proliferative.

The following significant correlations were found with the presence of DR: older age (p<0.001), longer duration of type 1 diabetes (p<0.001), earlier onset of type 1 diabetes (p<0.04), higher HbA1c (p<0.001), and high systolic and diastolic BP (each p<0.001). They also pointed out that these correlations remained significant after adjusting for age, gender, HbA1c, duration of type 1 diabetes and the age at onset of type 1 diabetes.

A subset of 109 eyes (69 patients) who had SD-OCT images and no DR had higher HbA1c values that were associated significantly with thinner central subfield thickness (p = 0.001) and thinner IRL (p=0.004). Higher systolic BP also was correlated significantly with increased IRL volume (p=0.02). No significant relationships were identified between the total IRL or ORL thickness and the BMI, diastolic BP or duration of type 1 diabetes.

The study underscored the significant associations seen with older age, longer disease duration, earlier disease onset and some modifiable risk factors, and the importance of controlling BP and HbA1c to prevent disease onset.

In addition, the correlation between higher HbA1c and thinner IRL in eyes without DR may mean that neurodegeneration is associated with worse glycemic and BP control. The authors emphasised that their results highlight the importance of controlling modifiable risk factors to prevent DR and potentially reduce subclinical neural retinal loss in young patients with type 1 diabetes.

Reference

Sampani K, Keady J, Silva PS, et al. Risk factors for diabetic retinopathy and neural retinal degeneration in youth with type 1 diabetes. Paper presented at the Association for Research in Vision and Ophthalmology annual meeting; May 5-9, 2024, Seattle, WA. Presentation number: 956

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.